NCT05870995View on ClinicalTrials.gov

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

September 1, 2026

Conditions
Refractory Leukemia
Interventions
DRUG

CALGE-VEN- RIC-conditioning

Intensive chemotherapy Cladribine-cytarabine-etoposide -venetoclax sequential with fludarabine, busulfan and melphalan or fludarabine and total marrow irradiation

Trial Locations (3)

200025

RECRUITING

Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai

Unknown

RECRUITING

Department of Hematology, Shanghai No 6 Hospital, Shanghai

RECRUITING

Shanghai ZhaXin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER